期刊
ALZHEIMERS & DEMENTIA
卷 12, 期 3, 页码 281-291出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2015.09.010
关键词
Amyloid; APOE; Alzheimer's disease; Cognitive aging; Cohort studies; PET
资金
- National Institutes of Health/National Institute on Aging [U01 AG006786, RO1 AG011378, R01 AG041851]
- Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program
- Walter S. and Lucienne Driskill Foundation
- Elsie and Marvin Dekelboum Family Foundation
- Rochester Epidemiology Project [R01 AG034676]
Introduction: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. Methods: We included 464 cognitively normal, test-naive, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51-71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow-up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline. Results: Elevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE 34 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test. Discussion: Elevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据